disease 2,452 words KG: ent-dise-93f3d65f 2026-03-31
kind:diseasesection:diseasesstate:publishedtopic:alstopic:ftdtopic:parkinsonismtopic:atypical-parkinsonism
Contents

ALS-FTD-Parkinsonism Comparison Matrix

Disease Info
ALS30-40% of familial, 5-10% of sporadic cases
FTD20-30% of familial bvFTD
Parkinsonism3-5% of cases, especially with dementia
CBS5-10% of cases
DatabasesOMIMOrphanetClinicalTrialsPubMed

Knowledge Graph

Related Hypotheses (30)

R-Loop Resolution Enhancement Therapy
Score: 0.43
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41

Related Analyses (25)

CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed
How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed

Related Experiments (30)

cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95
TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90
TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90
cGAMP biomarker analysis in ALS patient spinal cord samples
clinical · proposed · Score: 0.85
cGAMP biomarker analysis in ALS patient spinal cord samples
exploratory · proposed · Score: 0.80